To compare aprepitant with placebo in addition to standard antiemetic prophylaxis in preventing acute (days 1 through 5) and delayed (days 6 through 8) CINV measured by the proportion of patients with a Complete Response. 2 months [clinicaltrials_resource:3bcc644f94a662b1d42877a7c43f3e3c]
Arm A, Study Cycle 1
Arm B, Study Cycle 2
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
To compare aprepitant with placebo in addition to standard antiemetic prophylaxis in preventing acute (days 1 through 5) and delayed (days 6 through 8) CINV measured by the proportion of patients with a Complete Response. 2 months [clinicaltrials_resource:3bcc644f94a662b1d42877a7c43f3e3c]
Arm A, Study Cycle 1
Arm B, Study Cycle 2
Bio2RDF identifier
3bcc644f94a662b1d42877a7c43f3e3c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:3bcc644f94a662b1d42877a7c43f3e3c
measure [clinicaltrials_vocabulary:measure]
To compare aprepitant with pla ...... ents with a Complete Response.
time frame [clinicaltrials_vocabulary:time-frame]
description
Arm A, Study Cycle 1
Arm B, Study Cycle 2
identifier
clinicaltrials_resource:3bcc644f94a662b1d42877a7c43f3e3c
title
To compare aprepitant with pla ...... a Complete Response. 2 months
@en
type
label
To compare aprepitant with pla ...... c644f94a662b1d42877a7c43f3e3c]
@en